167 related articles for article (PubMed ID: 21345638)
1. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.
Slichter SJ; Bolgiano D; Kao KJ; Kickler TS; McFarland J; McCullough J; Woodson R
Transfus Med Rev; 2011 Apr; 25(2):102-10. PubMed ID: 21345638
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
3. Alloimmunization following platelet transfusions in patients with acute nonlymphocytic leukemia.
Nozaki H; Shimizu M; Komatsuda M; Watanabe K; Nagao T; Arimori S
Tokai J Exp Clin Med; 1986 Aug; 11(3):201-4. PubMed ID: 3475819
[TBL] [Abstract][Full Text] [Related]
4. Platelet refractoriness and alloimmunization.
Slichter SJ
Leukemia; 1998 Sep; 12 Suppl 1():S51-3. PubMed ID: 9777897
[TBL] [Abstract][Full Text] [Related]
5. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
[TBL] [Abstract][Full Text] [Related]
7. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
8. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
[TBL] [Abstract][Full Text] [Related]
9. Alloimmunization following platelet transfusion: the absence of a dose-response relationship.
Dutcher JP; Schiffer CA; Aisner J; Wiernik PH
Blood; 1981 Mar; 57(3):395-8. PubMed ID: 7459428
[TBL] [Abstract][Full Text] [Related]
10. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.
Slichter SJ; Davis K; Enright H; Braine H; Gernsheimer T; Kao KJ; Kickler T; Lee E; McFarland J; McCullough J; Rodey G; Schiffer CA; Woodson R
Blood; 2005 May; 105(10):4106-14. PubMed ID: 15692069
[TBL] [Abstract][Full Text] [Related]
12. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
[TBL] [Abstract][Full Text] [Related]
13. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization.
Murphy MF; Metcalfe P; Thomas H; Eve J; Ord J; Lister TA; Waters AH
Br J Haematol; 1986 Mar; 62(3):529-34. PubMed ID: 3954967
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
15. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model.
Slichter SJ; Pellham E; Bailey SL; Christoffel T; Gettinger I; Gaur L; Latchman Y; Nelson K; Bolgiano D
Blood; 2017 Aug; 130(8):1052-1061. PubMed ID: 28705838
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
Blundell EL; Pamphilon DH; Fraser ID; Menitove JE; Greenwalt TJ; Snyder EL; Repucci AJ; Hedberg SL; Anderson JK; Buchholz DH; Kagen LR; Aster RH
Transfusion; 1996 Apr; 36(4):296-302. PubMed ID: 8623127
[TBL] [Abstract][Full Text] [Related]
17. Platelet transfusion therapy.
Slichter SJ
Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
[TBL] [Abstract][Full Text] [Related]
18. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
[TBL] [Abstract][Full Text] [Related]
20. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
